{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:12:12Z","timestamp":1791306732674,"version":"4.3.1"},"reference-count":67,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2015,8,13]],"date-time":"2015-08-13T00:00:00Z","timestamp":1439424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0135556","type":"journal-article","created":{"date-parts":[[2015,8,13]],"date-time":"2015-08-13T13:57:25Z","timestamp":1439474245000},"page":"e0135556","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":91,"title":["Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning"],"prefix":"10.1371","volume":"10","author":[{"given":"Marcel","family":"Kaiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"M\u00e4ser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leela Pavan","family":"Tadoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Robert","family":"Ioset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,8,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/0-387-33026-7_3","article-title":"The neglected tropical diseases: The ancient afflictions of stigma and poverty and the prospects for their control and elimination","volume":"582","author":"P Hotez","year":"2006","journal-title":"Adv Exp Med Biol"},{"key":"ref2","unstructured":"World Health Organization (2014) Media centre. Leishmaniasis Fact sheet N\u00b0375, Updated January 2014. Available: www.who.int\/mediacentre\/factsheets\/fs375<\/ext-link>."},{"key":"ref3","unstructured":"World Health Organization (2014) Media centre. Trypanosomiasis, human African (sleeping sickness) Fact sheet N\u00b0259, Updated March 2014. Available: www.who.int\/mediacentre\/factsheets\/fs259<\/ext-link>."},{"key":"ref4","unstructured":"World Health Organization (2013) Media centre. Chagas disease (American trypanosoniasis) Fact sheet N\u00b0340, Updated March 2013. Available: www.who.int\/mediacentre\/factsheets\/fs340<\/ext-link>."},{"key":"ref5","unstructured":"World Health Organization (2014) Media centre. Malaria Fact sheet N\u00b094, Updated December 2014. Available: www.who.int\/mediacentre\/factsheets\/fs094<\/ext-link>."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1056\/NEJMc0805011","article-title":"Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium. Evidence of artemisinin-resistant malaria in western Cambodia","volume":"359","author":"H Noedl","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"JP Hughes","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"23\u201324","key":"ref8","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.drudis.2013.07.002","article-title":"Integration of models and experimentation to optimise the production of potential biotherapeutics","volume":"18","author":"KE Royle","year":"2013","journal-title":"Drug Discov Today"},{"key":"ref9","unstructured":"DNDi (2013) Target Product Profiles. Available: http:\/\/www.dndi.org\/diseases-projects\/diseases.html<\/ext-link>."},{"key":"ref10","unstructured":"MMV (2013) Target Product Profiles. Available: http:\/\/www.mmv.org\/research-development\/essential-information-scientists<\/ext-link>."},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1747-0285.2006.00391.x","article-title":"Searching for new antimalarial therapeutics amongst known drugs","volume":"67","author":"JL Weisman","year":"2006","journal-title":"Chem Biol Drug Des"},{"issue":"7154","key":"ref12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/448645a","article-title":"New uses for old drugs","volume":"9","author":"CR Chong","year":"2007","journal-title":"Nature"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/md8010047","article-title":"Inhibitory activity of marine sponge-derived natural products against parasitic protozoa","volume":"8","author":"I Orhan","year":"2010","journal-title":"Mar. Drugs"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1017\/S003118201300142X","article-title":"Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections","volume":"141","author":"R Don","year":"2014","journal-title":"Parasitology"},{"key":"ref15","unstructured":"MMV (2008) Compound progression criteria. Available: http:\/\/www.mmv.org\/research-development\/essential-information-scientists<\/ext-link>."},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/nar\/gkm1180","article-title":"Pentamidine binds to tRNA through non-specific hydrophobic interactions and inhibits aminoacylation and translation","volume":"36","author":"T Sun","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1128\/AAC.00192-06","article-title":"Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes","volume":"50","author":"AM Mathis","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.bcp.2010.02.009","article-title":"Mode of action of Nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: Is oxidative stress involved?","volume":"79","author":"M Boiani","year":"2010","journal-title":"Biochem Pharmacol"},{"issue":"15","key":"ref19","doi-asserted-by":"crossref","first-page":"13088","DOI":"10.1074\/jbc.M111.230847","article-title":"Nifurtimox Activation by Trypanosomal Type I Nitroreductases Generates Cytotoxic Nitrile Metabolites","volume":"286","author":"BS Hall","year":"2011","journal-title":"J Biol Chem"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"e923","DOI":"10.1371\/journal.pntd.0000923","article-title":"Fexinidazole\u2014A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness","volume":"4","author":"E Torreele","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/mutage\/ges015","article-title":"Genotoxicity profile of fexinidazole-a drug candidate in clinical development for human African trypanomiasis (sleeping sickness)","volume":"27","author":"D Tweats","year":"2012","journal-title":"Mutagenesis"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/emm.2003.9","article-title":"Gold compound auranofin inhibits I kappa B kinase (IKK) by modifying Cys-179 of IKK beta subunit","volume":"35","author":"KI Jeon","year":"2003","journal-title":"Exp Mol Med"},{"issue":"14","key":"ref23","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1093\/nar\/gkl541","article-title":"Selenium metabolism in Trypanosoma: characterization of selenoproteomes and identification of a Kinetoplastida-specific selenoprotein","volume":"34","author":"AV Lobanov","year":"2006","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nm.2758","article-title":"A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target","volume":"18","author":"A Debnath","year":"2012","journal-title":"Nat Med"},{"key":"ref25","first-page":"90","article-title":"Pharmacokinetics of auranofin in animals","volume":"8","author":"AP Intoccia","year":"1982","journal-title":"J Rheumatol Suppl"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1128\/AAC.43.4.985","article-title":"The anti-influenza virus drug rimantadine has trypanocidal activity","volume":"43","author":"JM Kelly","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1128\/AAC.45.5.1360-1366.2001","article-title":"In vitro and in vivo activities of aminoadamantane and aminoalkylcyclohexane derivatives against Trypanosoma brucei","volume":"45","author":"JM Kelly","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"17","key":"ref28","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1039\/b804907f","article-title":"Design and synthesis of bioactive 1,2-annulated adamantane derivatives","volume":"6","author":"G Zoidis","year":"2008","journal-title":"Org Biomol Chem"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0966-842X(00)88942-8","article-title":"Understanding the mechanism of action of the anti-influenza virus drug amantadine","volume":"3","author":"LH Pinto","year":"1995","journal-title":"Trends Microbiol"},{"issue":"1\u20133","key":"ref30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0014-5793(02)03851-6","article-title":"The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine","volume":"535","author":"SD Griffin","year":"2003","journal-title":"FEBS Letters"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1128\/AAC.19.2.226","article-title":"Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults","volume":"19","author":"FG Hayden","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/AAC.31.5.826","article-title":"Rimantadine pharmacokinetics after single and multiple doses","volume":"31","author":"RJ Wills","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1128\/AAC.28.2.216","article-title":"Comparative single-dose pharmacokinetics of amantadine and rimantadine hydrochloride in young and elderly adults","volume":"28","author":"FG Hayden","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0022-3565(25)24483-4","article-title":"Transport of amantadine and rimantadine through the blood-brain barrier","volume":"244","author":"R Spector","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"ref35","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0960-894X(00)00154-2","article-title":"Synthesis and evaluation of 9,9-dimethylxanthene tricyclics against trypanothione reductase, Trypanosoma brucei, Trypanosoma cruzi and Leishmania donovani","volume":"10","author":"K Chibale","year":"2000","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"ref36","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/cmdc.200900097","article-title":"Improved tricyclic inhibitors of trypanothione reductase by screening and chemical synthesis","volume":"4","author":"JL Richardson","year":"2009","journal-title":"ChemMedChem"},{"issue":"13","key":"ref37","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1073\/pnas.0711014105","article-title":"A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes","volume":"105","author":"SR Wilkinson","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1371\/journal.pntd.0001870","article-title":"Fexinidazole: A Potential New Drug Candidate for Chagas Disease","volume":"6","author":"MT Bahia","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"ref39","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1128\/CMR.12.4.501","article-title":"Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance","volume":"12","author":"MA Ghannoum","year":"1999","journal-title":"Clin Microbiol Rev"},{"issue":"20","key":"ref40","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas' disease","volume":"370","author":"I Molina","year":"2014","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/srep04703","article-title":"Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development","volume":"4","author":"CB Moraes","year":"2014","journal-title":"Sci Rep"},{"issue":"10","key":"ref42","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4155\/fmc.11.77","article-title":"Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite","volume":"3","author":"T Seebeck","year":"2011","journal-title":"Future Med Chem"},{"issue":"15","key":"ref43","doi-asserted-by":"crossref","first-page":"11788","DOI":"10.1074\/jbc.M111.326777","article-title":"Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors","volume":"287","author":"H Wang","year":"2012","journal-title":"J Biol Chem"},{"issue":"5","key":"ref44","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1021\/jm3017877","article-title":"Discovery of novel Trypanosoma brucei phosphodiesterase B1 inhibitors by virtual screening against the unliganded TbrPDEB1 crystal structure","volume":"56","author":"C Jansen","year":"2013","journal-title":"J Med Chem"},{"issue":"8","key":"ref45","doi-asserted-by":"crossref","first-page":"e23852","DOI":"10.1371\/journal.pone.0023852","article-title":"Identification of Novel Functional Inhibitors of Acid Sphingomyelinase","volume":"6","author":"J Kornhuber","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"ref46","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1128\/AAC.02398-12","article-title":"Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay","volume":"57","author":"M De Rycker","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ref47","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2174\/138920009788898019","article-title":"Amphotericin B and Its New Derivatives\u2014Mode of Action","volume":"10","author":"M Baginski","year":"2009","journal-title":"Curr Drug Metab"},{"issue":"2","key":"ref48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1051\/parasite\/2011182115","article-title":"Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance","volume":"18","author":"PM Loiseau","year":"2011","journal-title":"Parasite"},{"issue":"2","key":"ref49","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkr444","article-title":"Clofazimine: current status and future prospects","volume":"67","author":"MC Cholo","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"ref50","doi-asserted-by":"crossref","first-page":"e47494","DOI":"10.1371\/journal.pone.0047494","article-title":"Macrophages Sequester Clofazimine in an Intracellular Liquid Crystal-Like Supramolecular Organization","volume":"7","author":"J Baik","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"ref51","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/00034983.1989.11812371","article-title":"Antileishmanial effects of clofazimine and other antimycobacterial agents","volume":"83","author":"AT Evans","year":"1989","journal-title":"Ann Trop Med Parasitol"},{"issue":"2","key":"ref52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0190-9622(95)90134-5","article-title":"Clofazimine: a review of its medical uses and mechanisms of action","volume":"32","author":"JL Arbiser","year":"1995","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"ref53","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1128\/AAC.00055-12","article-title":"Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing","volume":"56","author":"DA Davis","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref54","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1021\/cb400800q","article-title":"Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity","volume":"9","author":"ER Sharlow","year":"2014","journal-title":"ACS Chem Biol"},{"issue":"7","key":"ref55","doi-asserted-by":"crossref","first-page":"e21237","DOI":"10.1371\/journal.pone.0021237","article-title":"Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies","volume":"6","author":"J Penna-Coutinho","year":"2011","journal-title":"PLoS One"},{"issue":"5256","key":"ref56","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/227381b0","article-title":"Inhibition of rodent malaria in mice by rifampicin","volume":"227","author":"NE Alger","year":"1970","journal-title":"Nature"},{"issue":"2","key":"ref57","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0035-9203(93)90497-E","article-title":"Antimalarial activity of rifampicin in vitro and in rodent models","volume":"87","author":"M Strath","year":"1993","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"4883","key":"ref58","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.3057629","article-title":"Reversal of chloroquine resistance in malaria parasite Plasmodium falciparum by desipramine","volume":"242","author":"AJ Bitonti","year":"1988","journal-title":"Science"},{"issue":"1","key":"ref59","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1128\/AAC.00920-12","article-title":"A class of tricyclic compounds blocking malaria parasite oocyst development and transmission","volume":"57","author":"RT Eastman","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"ref60","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s00436-002-0690-8","article-title":"Effects of dipyridamole on Plasmodium falciparum-infected erythrocytes","volume":"88","author":"M Akaki","year":"2002","journal-title":"Parasitol Res"},{"issue":"4","key":"ref61","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1128\/AAC.01043-07","article-title":"New active drugs against liver stages of Plasmodium predicted by molecular topology","volume":"52","author":"N Mahmoudi","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"ref62","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"TT Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"ref63","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","article-title":"Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines","volume":"19","author":"G Jin","year":"2014","journal-title":"Drug Discov Today"},{"issue":"11","key":"ref64","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.4155\/fmc.11.95","article-title":"Drug repositioning in the treatment of malaria and TB","volume":"3","author":"A Nzila","year":"2011","journal-title":"Future Med Chem"},{"issue":"2","key":"ref65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4103\/0022-3859.81870","article-title":"Drug repositioning: re-investigating existing drugs for new therapeutic indications","volume":"57","author":"BM Padhy","year":"2011","journal-title":"J Postgrad Med"},{"issue":"7","key":"ref66","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered","volume":"10","author":"DC Swinney","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"ref67","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nchembio806","article-title":"A clinical drug library screen identifies astemizole as an antimalarial agent","volume":"2","author":"CR Chong","year":"2006","journal-title":"Nat Chem Biol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0135556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T20:12:06Z","timestamp":1748549526000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0135556"}},"subtitle":[],"editor":[{"given":"David J.","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,8,13]]},"references-count":67,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0135556","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,13]]}}}